Ubs Group Ag Dr Reddys Laboratories LTD Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Dr Reddys Laboratories LTD stock. As of the latest transaction made, Ubs Group Ag holds 17,217 shares of RDY stock, worth $271,856. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,217

Previous 37,028 53.5%

Holding current value

$271,856

Previous $2.82 Million 51.54%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$75.41 - $84.21 $1.49 Million - $1.67 Million	-19,811 Reduced 53.5%	17,217 $1.37 Million
Q2 2024 Aug 13, 2024	SELL	$68.26 - $76.19 $723,351 - $807,385	-10,597 Reduced 22.25%	37,028 $2.82 Million
Q1 2024 May 13, 2024	BUY	$67.36 - $77.59 $2.2 Million - $2.53 Million	32,612 Added 217.23%	47,625 $3.49 Million
Q4 2023 Feb 09, 2024	SELL	$64.27 - $69.9 $57,585 - $62,630	-896 Reduced 5.63%	15,013 $1.04 Million
Q3 2023 Nov 09, 2023	BUY	$61.9 - $72.77 $27,978 - $32,892	452 Added 2.92%	15,909 $1.06 Million
Q2 2023 Aug 11, 2023	BUY	$53.34 - $63.11 $22,242 - $26,316	417 Added 2.77%	15,457 $975,000
Q1 2023 May 12, 2023	SELL	$51.63 - $56.93 $78,374 - $86,419	-1,518 Reduced 9.17%	15,040 $856,000
Q4 2022 Feb 08, 2023	SELL	$51.15 - $57.45 $71,251 - $80,027	-1,393 Reduced 7.76%	16,558 $856,000
Q3 2022 Nov 10, 2022	BUY	$49.9 - $57.32 $119,660 - $137,453	2,398 Added 15.42%	17,951 $940,000
Q2 2022 Aug 10, 2022	SELL	$49.62 - $58.13 $1.57 Million - $1.84 Million	-31,721 Reduced 67.1%	15,553 $861,000
Q1 2022 May 16, 2022	BUY	$48.27 - $65.25 $650,196 - $878,917	13,470 Added 39.85%	47,274 $2.63 Million
Q4 2021 Feb 14, 2022	BUY	$59.5 - $67.25 $1.03 Million - $1.17 Million	17,371 Added 105.71%	33,804 $2.21 Million
Q3 2021 Nov 15, 2021	BUY	$60.19 - $75.29 $236,727 - $296,115	3,933 Added 31.46%	16,433 $1.07 Million
Q2 2021 Aug 13, 2021	SELL	$62.12 - $74.2 $69,139 - $82,584	-1,113 Reduced 8.18%	12,500 $919,000
Q1 2021 May 12, 2021	SELL	$57.98 - $73.08 $205,075 - $258,483	-3,537 Reduced 20.62%	13,613 $835,000
Q4 2020 Feb 11, 2021	SELL	$62.61 - $71.29 $403,959 - $459,963	-6,452 Reduced 27.34%	17,150 $1.22 Million
Q3 2020 Nov 12, 2020	SELL	$51.39 - $72.41 $163,317 - $230,118	-3,178 Reduced 11.87%	23,602 $1.64 Million
Q2 2020 Jul 31, 2020	SELL	$39.55 - $54.65 $917,599 - $1.27 Million	-23,201 Reduced 46.42%	26,780 $1.42 Million
Q1 2020 May 01, 2020	SELL	$34.75 - $45.85 $208,048 - $274,503	-5,987 Reduced 10.7%	49,981 $2.02 Million
Q4 2019 Feb 14, 2020	SELL	$36.66 - $41.78 $23,828 - $27,157	-650 Reduced 1.15%	55,968 $2.27 Million
Q3 2019 Nov 14, 2019	SELL	$34.82 - $39.26 $35,760 - $40,320	-1,027 Reduced 1.78%	56,618 $2.15 Million
Q2 2019 Aug 14, 2019	SELL	$36.05 - $42.76 $107,068 - $126,997	-2,970 Reduced 4.9%	57,645 $2.16 Million
Q1 2019 May 14, 2019	SELL	$35.77 - $40.57 $210,542 - $238,795	-5,886 Reduced 8.85%	60,615 $2.46 Million
Q4 2018 Feb 14, 2019	BUY	$31.89 - $38.44 $144,812 - $174,556	4,541 Added 7.33%	66,501 $2.51 Million
Q3 2018 Nov 14, 2018	SELL	$29.25 - $36.73 $47,326 - $59,429	-1,618 Reduced 2.54%	61,960 $2.14 Million
Q2 2018 Aug 14, 2018	BUY	$28.49 - $35.06 $106,752 - $131,369	3,747 Added 6.26%	63,578 $2.05 Million
Q1 2018 May 15, 2018	BUY	$31.93 - $39.54 $194,773 - $241,194	6,100 Added 11.35%	59,831 $1.96 Million
Q4 2017 Feb 14, 2018	SELL	$34.15 - $37.62 $12.9 Million - $14.2 Million	-377,900 Reduced 87.55%	53,731 $2.02 Million
Q3 2017 Nov 14, 2017	BUY	$30.11 - $37.72 $10.1 Million - $12.7 Million	336,439 Added 353.43%	431,631 $15.4 Million
Q2 2017 Aug 14, 2017	SELL	N/A	-8,562 Reduced 8.25%	95,192 $4.01 Million
Q1 2017 Nov 14, 2017	BUY	N/A	103,754	103,754 $4.17 Million

Others Institutions Holding RDY

# of Institutions

245

Shares Held

23.1M

Call Options Held

12.7K

Put Options Held

6.1K

View Full List

About DR REDDYS LABORATORIES LTD

Ticker RDY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 166,028,992
Market Cap $2.62B
Description
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-t...

More about RDY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account